BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang D, Zhuang B, Wang Y, Xie X, Xie X. Radiofrequency ablation versus hepatic resection for recurrent hepatocellular carcinoma: an updated meta-analysis. BMC Gastroenterol 2020;20:402. [PMID: 33246417 DOI: 10.1186/s12876-020-01544-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Xie Q, Yang Y, Qu B, Xiao P, Tang F, Shen H. Comparison of surgical resection and radiofrequency ablation for stages I and II elderly hepatocellular carcinoma patients (≥ 65 years): A SEER population-based propensity score matching’s study. Front Oncol 2022;12:903231. [DOI: 10.3389/fonc.2022.903231] [Reference Citation Analysis]
2 Yeow M, Zhao JJ, Fong KY, Wong J, Tan AYH, Kam JH, Nikfarjam M, Goh BKP, Kabir T. Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. World J Surg. [DOI: 10.1007/s00268-022-06691-x] [Reference Citation Analysis]
3 Zou YW, Ren ZG, Sun Y, Liu ZG, Hu XB, Wang HY, Yu ZJ. The latest research progress on minimally invasive treatments for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00190-4. [PMID: 36041973 DOI: 10.1016/j.hbpd.2022.08.004] [Reference Citation Analysis]
4 Deng Q, He M, Fu C, Feng K, Ma K, Zhang L. Radiofrequency ablation in the treatment of hepatocellular carcinoma. Int J Hyperthermia 2022;39:1052-63. [PMID: 35944905 DOI: 10.1080/02656736.2022.2059581] [Reference Citation Analysis]
5 Wei M, Zhang Y, Chen M, Chen Y, Lau W, Peng Z. Adjuvant Sorafenib Following Radiofrequency Ablation for Early-Stage Recurrent Hepatocellular Carcinoma With Microvascular Invasion at the Initial Hepatectomy. Front Oncol 2022;12:868429. [DOI: 10.3389/fonc.2022.868429] [Reference Citation Analysis]
6 Gou H, Liu S, Zhu G, Peng Y, Li X, Yang X, He K. Effectiveness of radiofrequency ablation versus transarterial chemoembolization for recurrent hepatocellular carcinoma: A meta-analysis. Acta Radiologica Open 2022;11:205846012210855. [DOI: 10.1177/20584601221085514] [Reference Citation Analysis]
7 Ma L, Deng K, Zhang C, Li H, Luo Y, Yang Y, Li C, Li X, Geng Z, Xie C. Nomograms for Predicting Hepatocellular Carcinoma Recurrence and Overall Postoperative Patient Survival. Front Oncol 2022;12:843589. [PMID: 35296018 DOI: 10.3389/fonc.2022.843589] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Liu B, Fu D, Fan Y, Wang Z, Lang X. Irreversible electroporation versus radiofrequency ablation for malignant hepatic tumor: A prospective single-center double-arm trial. Journal of Interventional Medicine 2022. [DOI: 10.1016/j.jimed.2022.03.010] [Reference Citation Analysis]
9 Yang Y, Yu H, Tan X, You Y, Liu F, Zhao T, Qi J, Li J, Feng Y, Zhu Q. Liver resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia 2021;38:875-86. [PMID: 34078221 DOI: 10.1080/02656736.2021.1933218] [Reference Citation Analysis]